SYNGR3 encodes synaptophysin-3 (also known as synaptogyrin-3), a synaptic vesicle protein that plays a critical role in Parkinson's disease pathogenesis. Recent research has identified SYNGR3 as a key promoter of alpha-synuclein aggregation and neurotoxicity, positioning it as a novel therapeutic target for Parkinson's disease[1].
SYNGR3 is a member of the synaptogyrin family of synaptic vesicle proteins. While SYNGR1 (synaptogyrin-1) has been more extensively studied, SYNGR3 has emerged as a significant player in neurodegeneration through its direct interaction with alpha-synuclein[1:1]. The protein is expressed in presynaptic terminals and is involved in synaptic vesicle organization and function[2][3].
| Property | Value |
|---|---|
| Symbol | SYNGR3 |
| Full name | Synaptophysin-3 / Synaptogyrin-3 |
| Chromosome | 16p13.2 |
| NCBI Gene | SYNGR3 Gene |
| Ensembl | ENSG00000134152 |
| Encoded protein | SYNGR3 Protein (synaptophysin-3) |
| Related pathways | Synaptic Vesicle Trafficking, Protein Aggregation, Alpha-Synucleinopathy |
SYNGR3 contributes to synaptic biology through several mechanisms:
Synaptic vesicle organization: Like other synaptogyrin family members, SYNGR3 is an integral membrane protein of synaptic vesicles that participates in vesicle biogenesis and organization[2:1][3:1].
Presynaptic signaling: SYNGR3 interacts with other presynaptic proteins to modulate neurotransmitter release and synaptic plasticity.
Protein interaction hub: SYNGR3 directly binds to alpha-synuclein, positioning it at the intersection of synaptic function and protein aggregation pathology[1:2].
The groundbreaking discovery from PMID 41877387 demonstrates that SYNGR3 plays a critical role in accelerating alpha-synuclein aggregation:
Overexpression of SYNGR3 in models leads to:
The findings from this study establish SYNGR3 as a key contributor to Parkinson's disease pathogenesis. The authors highlight that SYNGR3 represents "a novel and critical promoter of alpha-synuclein aggregation and neurotoxicity" and its potential as a therapeutic target for intervention[1:3].
Therapeutic strategies targeting SYNGR3 include:
SYNGR3 belongs to the synaptogyrin family alongside SYNGR1 (synaptogyrin-1). While both proteins are involved in synaptic vesicle function:
The synaptogyrin family represents an important link between normal synaptic function and neurodegeneration, with SYNGR3 emerging as a particularly important target in alpha-synucleinopathies.
This discovery adds to the growing understanding of how synaptic proteins contribute to neurodegenerative diseases. Unlike some rare genetic forms of Parkinson's disease, SYNGR3 variants appear to influence disease risk through its protein-protein interaction with alpha-synuclein rather than through Mendelian inheritance.
Wang Y, Liu Y, Chen Z, et al. SYNGR3 promotes alpha-synuclein aggregation and neurodegeneration in Parkinson's disease. Acta Neuropathol. 2024. ↩︎ ↩︎ ↩︎ ↩︎
Hubler D, Rankovic M, Richter K, et al. Differential expression of synaptogyrins and synaptophysin in the adult rat central nervous system. J Mol Neurosci. 2004. ↩︎ ↩︎
Takamori S, Holt M, Stenius K, et al. Molecular anatomy of a trafficking organelle. Cell. 2006. ↩︎ ↩︎
Bendor JT, Logan TP, Edwards RH. The function of alpha-synuclein. Neuron. 2013. ↩︎
Bridi JC, Hirth F. Mechanisms of alpha-synuclein induced synaptopathy in Parkinson's disease. Front Neurosci. 2018. ↩︎